The clinical advances of fluorine-2-D-deoxyglucose-positron emission tomography/computed tomography in urological cancers

International Journal of Urology

Volumn 17, Issue 6, 2010, Pages 501-511

  Avril, Norbert ^a   Dambha, Fatima ^a   Murray, Iain ^a   Shamash, Jonathan ^a   Powles, Tom ^a   Sahdev, Anju ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Diagnosis; Fluorine 18 labeled fluorine 2 D deoxyglucose positron emission tomography; Positron emission tomography; Positron emission tomography computed tomography urological tumors; Staging; Treatment monitoring

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

BLADDER CANCER; BONE METASTASIS; CANCER TISSUE; CASTRATION; CELL VIABILITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE COURSE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; HUMAN; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LUNG METASTASIS; NON SEMINOMATOUS GERMINOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SEMINOMATOUS GERMINOMA; TERATOMA; TISSUE METABOLISM; UPREGULATION; URINARY EXCRETION; URINARY TRACT CANCER; CANCER STAGING; CARCINOMA, RENAL CELL; DIAGNOSTIC USE; KIDNEY NEOPLASMS; MALE; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

CARCINOMA, RENAL CELL; FLUORODEOXYGLUCOSE F18; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 77952688903     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02509.x     Document Type: Review

References (51)

1. Fletcher JW, Djulbegovic B, Soares HP et al. Recommendations on the use of 18F-FDG PET in oncology. J. Nucl. Med. 2008 49: 480 508.
2. Weber WA. Positron emission tomography as an imaging biomarker. J. Clin. Oncol. 2006 24: 3282 3292.
3. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J. Nucl. Med. 2004 45: 4S 14S.
4. Beyer T, Townsend DW, Brun T et al. A combined PET/CT scanner for clinical oncology. J. Nucl. Med. 2000 41: 1369 1379.
5. Avril NE, Weber WA. Monitoring response to treatment in patients utilizing PET. Radiol. Clin. North Am. 2005 43: 189 204.
6. Andrade RS, Heron DE, Degirmenci B et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int. J. Radiat. Oncol. Biol. Phys. 2006 65: 1315 1322.
7. Juweid ME, Stroobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J. Clin. Oncol. 2007 25: 571 578.
8. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993 189: 847 850.
9. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995 196: 167 173.
10. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J. Nucl. Med. 1999 40: 1771 1777.
11. Hain SF, Maisey MN. Positron emission tomography for urological tumours. BJU Int. 2003 92: 159 164.
12. Wilson CB, Young HE, Ott RJ et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management. Eur. J. Nucl. Med. 1995 22: 508 513.
13. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J. Urol. 1995 154: 1045 1049.
14. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors. Urology 1999 53: 808 811. (Pubitemid 29163051) (Pubitemid 29163051)
15. 18fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. BJU Int. 2002 89: 549 556.
16. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur. J. Nucl. Med. 2000 27: 590 594.
17. Cremerius U, Wildberger JE, Borchers H et al. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients. Urology 1999 54: 900 904.
18. De Wit M, Brenner W, Hartmann M et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. Ann. Oncol. 2008 19: 1619 1623.
19. Sohaib SA, Koh DM, Husband JE. The role of imaging in the diagnosis, staging, and management of testicular cancer. AJR Am. J. Roentgenol. 2008 191: 387 395.
20. Huddart RA, O'Doherty MJ, Padhani A et al. 18fluorodeoxyglucose positron emission tomography in the prediction of relapse in patients with high-risk, clinical stage I nonseminomatous germ cell tumors: preliminary report of MRC Trial TE22-the NCRI Testis Tumour Clinical Study Group. J. Clin. Oncol. 2007 25: 3090 3095.
21. Lassen U, Daugaard G, Eigtved A, Hojgaard L, Damgaard K, Rorth M. Whole-body FDG-PET in patients with stage I non-seminomatous germ cell tumours. Eur. J. Nucl. Med. Mol. Imaging 2003 30: 396 402.
22. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br. J. Cancer 2000 83: 863 869.
23. Sanchez D, Zudaire JJ, Fernandez JM et al. 18F-fluoro-2-deoxyglucose- positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. BJU Int. 2002 89: 912 916.
24. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J. Clin. Oncol. 2004 22: 1034 1039.
25. Becherer A, De Santis M, Karanikas G et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. Eur. J. Radiol. 2005 54: 284 288.
26. Muller-Mattheis V, Reinhardt M, Gerharz CD et al. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors]. Urologe A 1998 37: 609 620 In German W, Hanauske AR, Ziegler S et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood 1998 91: 4464 4471.
27. Pfannenberg AC, Oechsle K, Kollmannsberger C et al. [Early prediction of treatment response to high-dose chemotherapy in patients with relapsed germ cell tumors using [18F]FDG-PET, CT or MRI, and tumor marker]. Rofo 2004 176: 76 84 In German PJ, Bares R, Handt S, Wolff JM, Bull U, Jakse G. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose. J. Urol. 1996 155: 994 998.
28. Hofer C, Laubenbacher C, Block T, Breul J, Hartung R, Schwaiger M. Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy. Eur. Urol. 1999 36: 31 5.
29. Liu IJ, Zafar MB, Lai YH, Segall GM, Terris MK. Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer. Urology 2001 57: 108 111.
30. Oyama N, Akino H, Suzuki Y et al. Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer. Mol. Imaging Biol. 2002 4: 99 104.
31. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology 1996 199: 751 756.
32. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin. Nucl. Med. 2005 35: 135 142.
33. Morris MJ, Akhurst T, Osman I et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002 59: 913 918.
34. Yeh SD, Imbriaco M, Larson SM et al. Detection of bony metastases of androgen-independent prostate cancer by PET-FDG. Nucl. Med. Biol. 1996 23: 693 697.
35. Schoder H, Herrmann K, Gonen M et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin. Cancer Res. 2005 11: 4761 4769.
36. Seltzer MA, Barbaric Z, Belldegrun A et al. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 1999 162: 1322 1328.
37. Nunez R, Macapinlac HA, Yeung HW et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J. Nucl. Med. 2002 43: 46 55.
38. 18F]-2-deoxy-D-glucose. Eur. Urol. 1999 36: 582 587.
39. Oyama N, Akino H, Suzuki Y et al. FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation. Nucl. Med. Commun. 2001 22: 963 969.
40. Morris MJ, Akhurst T, Larson SM et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin. Cancer Res. 2005 11: 3210 3216.
41. Powles T, Murray I, Brock C, Oliver T, Avril N. Molecular positron emission tomography and PET/CT imaging in urological malignancies. Eur. Urol. 2007 51: 1511 1520, discussion 1520-1.
42. 18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT. Eur. J. Nucl. Med. Mol. Imaging 2003 30: 1236 1245.
43. Majhail NS, Urbain JL, Albani JM et al. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. J. Clin. Oncol. 2003 21: 3995 4000.
44. Kang DE, White RL Jr., Zuger JH, Sasser HC, Teigland CM. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. J. Urol. 2004 171: 1806 1809.
45. Kosuda S, Kison PV, Greenough R, Grossman HB, Wahl RL. Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer. Eur. J. Nucl. Med. 1997 24: 615 620.
46. Ahlstrom H, Malmstrom PU, Letocha H, Andersson J, Langstrom B, Nilsson S. Positron emission tomography in the diagnosis and staging of urinary bladder cancer. Acta Radiol. 1996 37: 180 185.
47. Bachor R, Kotzerke J, Reske SN, Hautmann R. [Lymph node staging of bladder neck carcinoma with positron emission tomography]. Urologe A 1999 38: 46 50 In German O, Oyen R, Van Poppel H, Vankan Y, Flamen P, Mortelmans L. FDG-PET for preoperative staging of bladder cancer. Eur. J. Nucl. Med. Mol. Imaging 2005 31: 31.
48. Kibel AS, Dehdashti F, Katz MD et al. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma. J. Clin. Oncol. 2009 27: 4314 4320.
49. Swinnen G, Maes A, Pottel H et al. FDG-PET/CT for the Preoperative Lymph Node Staging of Invasive Bladder Cancer. Eur. Urol. 2010 4: 641 647.
50. Liu IJ, Lai YH, Espiritu JI et al. Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy. Urol. Int. 2006 77: 69 75.
51. Jadvar H, Quan V, Henderson RW, Conti PS. [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma. Int. J. Clin. Oncol. 2008 13: 42 7.